US green light for cheaper anti-HIV drug
Published
US authorities have given the green light to a cheaper anti-HIV drug. This treatment is used for pre-exposure prophylaxis, known as PrEP, to prevent infection with the HIV virus.
PrEP involves taking a medication before a possible risk of contamination, in order to protect a person who is not ill. This treatment therefore reduces the risk of infection, but it does not cure HIV in people who are already infected.
It is important to point out that this product is not a vaccine. It does not act on the immune system in the same way as a vaccine, but it acts directly on the virus to block its establishment in the body.
The aim of this decision is to make prevention more accessible to a greater number of people. The information available is still limited, and further details on the final price and distribution conditions will need to be awaited.
Sources: Nessma TV
More France news
- Maxime Pavageau, 29, wins France's best young wine seller title
- A New, Highly Promising Concrete
- Paris and Île-de-France: Immersive Exhibitions to Experience Art Differently
- France 3 broadcasts a documentary on the history of the Téléthon, narrated by Zazie
- ChatGPT launches business profiles with mention and click statistics
- Trail: France Outdoor Seeks to Frame Environmental Restrictions
- A Roanne company bets on knitwear made in France
- Sport: Major Win for the Brûleurs de Loups and Six Internationals Absent for FC Annecy